Comprehensive genomic and immune profiling of non-V600 BRAF-mutated melanomas: Implications for therapeutic strategies beyond BRAF/MEK inhibitors. This is an ASCO Meeting Abstract from the 2024 ASCO ...
Patterns of care in adjuvant systemic therapy of patients with stage III melanoma: A U.S. population-based study.
Investigations suggest V2P may be efficiently applied for the automated identification of causal variants in simulated and actual patient sequencing data across phenotypes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback